Twenty-Four-Hour Symptom Control in Parkinson’s Disease, with Emphasis on Management of Nocturnal Disabilities

Chaudhuri, K. Ray

doi:10.1159/000058046

Cited by 1 publication

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is especially true when the drug is administered at night. We have observed, in an open parallel group study, that, compared with levodopa/carbidopa, patients taking an evening dose of cabergoline rated their sleep quality and clinical global state to be improved by 88% compared with 27% on levodopa/carbidopa 36 …”

Section: Clinical Studiesmentioning

confidence: 98%

“…We, and others, have reported the beneficial effect of sustained dopamine agonism, using evening dosing of cabergoline or nocturnal apomorphine infusion, on idiopathic and PD‐related RLS, and in particular its efficacy in RLS patients exhibiting levodopa‐related augmentation (extension of RLS symptoms to early evening or afternoon possibly due to use of short half‐life agents) 5,36,38,42–45 . Because cabergoline has a half‐life of 65 hours, it has the advantage of being active throughout the night on once‐daily dosage; the dose requirement for RLS varies between 2–4 mg/day.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…We have observed, in an open parallel group study, that, compared with levodopa/carbidopa, patients taking an evening dose of cabergoline rated their sleep quality and clinical global state to be improved by 88% compared with 27% on levodopa/ carbidopa. 36 A small comparative trial (33 patients on cabergoline and 28 on pergolide) reported that, when compared to pergolide, another commonly used dopamine agonist with a half-life of 7-16 hours, cabergoline was more effective in reducing nocturnal waking, early morning dystonia and dystonic pain. 37 A small multicentre, video-blinded, crossover trial comparing cabergoline (up to 6 mg once daily) and pergolide (up to 5 mg three times daily) reported similar motor improvement in both groups, although cabergoline was significantly more effective in improving 'off' period related motor scores after eight weeks of treatment.…”

Section: Additional Neurological Uses Of Cabergolinementioning

confidence: 99%

See 2 more Smart Citations

Treatment of Parkinson's Disease and Restless Legs Syndrome With Cabergoline, a Long‐acting Dopamine Agonist

Porter

Appiah-Kubf²,

Chaudhuri

2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYDopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in Parkinson's disease (PD). Cabergoline, a dopamine agonist effective given once daily, is being used as treatment for PD. In theory, therapy with cabergoline provides striatal intrasynaptic dopamine replacement of PD in a physiological manner because of its long half‐life and the resultant sustained rather than pulsatile dopaminergic stimulation. Several placebo‐controlled trials using cabergoline as adjunctive therapy in PD have shown that cabergoline significantly reduces ‘off’ time, improves motor function and reduces levodopa requirement. Cabergoline has also been used as monotherapy in PD and has been shown to be as effective as other dopamine agonists in improving motor function and to be superior to levodopa in reducing dyskinesias over a five‐year period. Work from our group and others have also demonstrated the efficacy of cabergoline in PD patients with nocturnal disabilities and those with restless legs syndrome (RLS). More recently we have reported that cabergoline is a well‐tolerated dopamine agonist in both young and elderly patients and has an acceptable side‐effect profile.

show abstract

Section: Clinical Studiesmentioning

confidence: 98%

Section: Clinical Studiesmentioning

confidence: 99%